These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries. Mosholder AD; Ma Y; Akhtar S; Podskalny GD; Feng Y; Lyu H; Liao J; Wei Y; Wernecke M; Leishear K; Nelson LM; MaCurdy TE; Kelman JA; Graham DJ Am J Psychiatry; 2022 Aug; 179(8):553-561. PubMed ID: 35702829 [TBL] [Abstract][Full Text] [Related]
50. Non-clinical pharmacology and toxicology studies of LPM6690061, a novel 5-hydroxytryptamine (5-HT) Zhu X; Yang Y; Du G; Liu B; Yu X; Ye L; Mao Y; Wang H; Tian J Food Chem Toxicol; 2023 Jun; 176():113800. PubMed ID: 37100235 [TBL] [Abstract][Full Text] [Related]
51. Inverse agonism and its therapeutic significance. Khilnani G; Khilnani AK Indian J Pharmacol; 2011 Sep; 43(5):492-501. PubMed ID: 22021988 [TBL] [Abstract][Full Text] [Related]
54. The role of serotonin 5-HT2A receptors in memory and cognition. Zhang G; Stackman RW Front Pharmacol; 2015; 6():225. PubMed ID: 26500553 [TBL] [Abstract][Full Text] [Related]
55. Pimavanserin and Parkinson's Disease Psychosis: A Narrative Review. Rissardo JP; Durante Í; Sharon I; Fornari Caprara AL Brain Sci; 2022 Sep; 12(10):. PubMed ID: 36291220 [TBL] [Abstract][Full Text] [Related]
56. When is a Proof-of-Concept (POC) not a POC? Pomaglumetad (LY2140023) as a Case Study for Antipsychotic Efficacy. Marek GJ Curr Pharm Des; 2015; 21(26):3788-96. PubMed ID: 26044978 [TBL] [Abstract][Full Text] [Related]
57. 5‑Hydroxytryptamine 2A receptor inverse agonist pimavanserin impairs maternal behavior in postpartum female rats. Gan L; Sun M; Chen W Pharmacol Biochem Behav; 2018 Dec; 175():152-159. PubMed ID: 30393120 [TBL] [Abstract][Full Text] [Related]
58. Pimavanserin (Nuplazid™) for the treatment of Parkinson disease psychosis: A review of the literature. Touma KTB; Touma DC Ment Health Clin; 2017 Sep; 7(5):230-234. PubMed ID: 29955528 [TBL] [Abstract][Full Text] [Related]
59. Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease. Price DL; Bonhaus DW; McFarland K Behav Pharmacol; 2012 Aug; 23(4):426-33. PubMed ID: 22750845 [TBL] [Abstract][Full Text] [Related]
60. New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin. Caraci F; Santagati M; Caruso G; Cannavò D; Leggio GM; Salomone S; Drago F F1000Res; 2020; 9():. PubMed ID: 32695312 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]